Great news:
https://www.foxnews.com/science/moderna-positive-phase-i-data-potential-coronavirus-vaccine
The Phase I trial of mRNA-1273 saw all patients receive a 25 microgram, 100 microgram or 250 microgram dose. Fifteen patients were in each group and those who participated in the study received two doses of the potential vaccine via an injection in the upper arm, 28 days apart.
At day 43, the group that received 25 micrograms, saw the same level of antibodies as people who had recovered from the disease. At day 43, the 100 microgram dose group saw levels of antibodies that "significantly exceeded the levels" seen in those who had recovered from the disease, the company added.